{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:07:44Z","timestamp":1789596464253,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s10157-011-0465-6","type":"journal-article","created":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T00:40:27Z","timestamp":1306284027000},"page":"641-647","source":"Crossref","is-referenced-by-count":16,"title":["Rituximab and minimal change nephrotic syndrome: a therapeutic option"],"prefix":"10.1007","volume":"15","author":[{"given":"Takashi","family":"Takei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,1]]},"reference":[{"key":"465_CR1","first-page":"319","volume":"16","author":"JS Cameron","year":"1996","unstructured":"Cameron JS. Nephrotic syndrome in the elderly. Semin Nephrol. 1996;16:319\u201329.","journal-title":"Semin Nephrol"},{"key":"465_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s10157-007-0484-5","volume":"11","author":"T Takei","year":"2007","unstructured":"Takei T, Koike M, Suzuki K, Shirota S, Itabashi M, Otsubo S, et al. The characteristics of relapse in adult-onset minimal change nephrotic syndrome. Clin Exp Nephrol. 2007;11:214\u20137.","journal-title":"Clin Exp Nephrol"},{"key":"465_CR3","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1097\/01.ASN.0000016406.82019.B3","volume":"13","author":"R Cunard","year":"2002","unstructured":"Cunard R, Lelly CJ. T cells and minimal change disease. J Am Soc Nephrol. 2002;13:1409\u201311.","journal-title":"J Am Soc Nephrol"},{"key":"465_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/ndt\/18.2.245","volume":"18","author":"P Grimbert","year":"2003","unstructured":"Grimbert P, Audard V, Remy P, Lang P, Sahai D. Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. Nephrol Dial Transplant. 2003;18:245\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"465_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.5414\/CNP60242","volume":"60","author":"MJ Kemper","year":"2003","unstructured":"Kemper MJ, Meyer-Jark T, Lilova M, Muller-Wiefel DE. Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol. 2003;60:242\u20137.","journal-title":"Clin Nephrol"},{"key":"465_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s10157-010-0330-z","volume":"14","author":"T Kanai","year":"2010","unstructured":"Kanai T, Shiraishi H, Yamagata T, Ito T, Odaka J, Saito T, et al. Th2 cells predominate in idiopathic steroid-sensitive nephrotic syndrome. Clin Exp Nephrol. 2010;14:578\u201383.","journal-title":"Clin Exp Nephrol"},{"key":"465_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJM199401063300102","volume":"330","author":"J Dantal","year":"1994","unstructured":"Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med. 1994;330:7\u201314.","journal-title":"N Engl J Med"},{"key":"465_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000085357","volume":"25","author":"MJ Kemper","year":"2005","unstructured":"Kemper MJ, Zepf K, Klaassen I, Link A, Muller-Wiefel DE. Changes of lymphocyte populations in pediatric steroid-sensitive nephrotic syndrome are more pronounced in remission than in relapse. Am J Nephrol. 2005;25:132\u20137.","journal-title":"Am J Nephrol"},{"key":"465_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00467-006-0427-5","volume":"22","author":"GC Smith","year":"2007","unstructured":"Smith GC. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr Nephrol. 2007;22:893\u20138.","journal-title":"Pediatr Nephrol"},{"key":"465_CR10","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/sj.bjc.6601187","volume":"89","author":"I Avivi","year":"2003","unstructured":"Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in haematological malignancies. Br J Cancer. 2003;89:1389\u201394.","journal-title":"Br J Cancer"},{"key":"465_CR11","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793\u2013806.","journal-title":"Arthritis Rheum"},{"key":"465_CR12","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1002\/art.22046","volume":"54","author":"KG Smith","year":"2006","unstructured":"Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and pre-treatment. Arthritis Rheum. 2006;54:2970\u201382.","journal-title":"Arthritis Rheum"},{"key":"465_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1172\/JCI110005","volume":"67","author":"LM Nadler","year":"1981","unstructured":"Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest. 1981;67:134\u201340.","journal-title":"J Clin Invest"},{"key":"465_CR14","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457\u201366.","journal-title":"Blood"},{"key":"465_CR15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435\u201345.","journal-title":"Blood"},{"key":"465_CR16","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3174\/ajnr.A2142","volume":"31","author":"DT Selewski","year":"2010","unstructured":"Selewski DT, Shah GV, Mody RJ, Rajdev PA, Mukherji SK. Rituximab (Rituxan). AJNR Am J Neuroradiol. 2010;31:1178\u201380.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5 Pt1","key":"465_CR17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"6","author":"MD Pescovitz","year":"2006","unstructured":"Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6(5 Pt1):859\u201366.","journal-title":"Am J Transplant"},{"key":"465_CR18","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1002\/art.20592","volume":"50","author":"JH Anolik","year":"2004","unstructured":"Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50:3580\u201390.","journal-title":"Arthritis Rheum"},{"key":"465_CR19","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321\u20138.","journal-title":"Pediatr Nephrol"},{"key":"465_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1023\/A:1008265313133","volume":"9","author":"K Tobinai","year":"1998","unstructured":"Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol. 1998;9:527\u201334.","journal-title":"Ann Oncol"},{"key":"465_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/01.TP.0000112934.12622.2B","volume":"77","author":"CA Vieira","year":"2004","unstructured":"Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1 Safety, pharmacodynamics, and pharmacokinetics. Transplantation. 2004;77:542\u20138.","journal-title":"Transplantation"},{"key":"465_CR22","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/j.1600-6143.2006.01497.x","volume":"6","author":"H Genberg","year":"2006","unstructured":"Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant. 2006;6:2418\u201328.","journal-title":"Am J Transplant"},{"key":"465_CR23","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825\u201333.","journal-title":"J Clin Oncol"},{"key":"465_CR24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/HAB-2004-13301","volume":"13","author":"RA Sidner","year":"2004","unstructured":"Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA, Pescovitz MD. In vivo human B-cell subset recovery after in vivo depeletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies. 2004;13:55\u201362.","journal-title":"Hum Antibodies"},{"key":"465_CR25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/ajkd.2003.50116","volume":"41","author":"F Fakhouri","year":"2003","unstructured":"Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux MF, Landais P, et al. Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis. 2003;41:550\u20137.","journal-title":"Am J Kidney Dis"},{"key":"465_CR26","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1007\/s00467-006-0228-x","volume":"21","author":"RD Gilbert","year":"2006","unstructured":"Gilbert RD, Hulse E, Rigden S. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol. 2006;21:1698\u2013700.","journal-title":"Pediatr Nephrol"},{"key":"465_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1053\/j.ajkd.2006.10.015","volume":"49","author":"H Francois","year":"2007","unstructured":"Francois H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis. 2007;49:158\u201361.","journal-title":"Am J Kidney Dis"},{"key":"465_CR28","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1093\/ndt\/gfm128","volume":"22","author":"JM Hofstra","year":"2007","unstructured":"Hofstra JM, Deegens JK, Wetzels JF. Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome? Nephrol Dial Transplant. 2007;22:2100\u20132.","journal-title":"Nephrol Dial Transplant"},{"key":"465_CR29","first-page":"408","volume":"66","author":"HP Peters","year":"2008","unstructured":"Peters HP, van de Kar NC, Wetzels JF. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature. Neth J Med. 2008;66:408\u201315.","journal-title":"Neth J Med"},{"key":"465_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/ndt\/gfm592","volume":"23","author":"T Yang","year":"2008","unstructured":"Yang T, Nast CC, Vo A, Jordan SC. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant. 2008;23:377\u201380.","journal-title":"Nephrol Dial Transplant"},{"key":"465_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5414\/CNP72069","volume":"72","author":"Y Sawara","year":"2009","unstructured":"Sawara Y, Itabashi M, Kojima C, Tabata H, Kamei D, Kawanishi K, et al. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. Clin Nephrol. 2009;72:69\u201372.","journal-title":"Clin Nephrol"},{"key":"465_CR32","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2169\/internalmedicine.48.2435","volume":"48","author":"N Kurosu","year":"2009","unstructured":"Kurosu N, Sugiura H, Iwasaki C, Asamiya Y, Kojima C, Moriyama T, et al. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern Med. 2009;48:1901\u20134.","journal-title":"Intern Med"},{"key":"465_CR33","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008;23:1269\u201379.","journal-title":"Pediatr Nephrol"},{"key":"465_CR34","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00467-010-1465-6","volume":"25","author":"AL Sellier-Leclerc","year":"2010","unstructured":"Sellier-Leclerc AL, Macher MA, Loirat C, Guerin V, Watier H, Peuchmaur M, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25:1109\u201315.","journal-title":"Pediatr Nephrol"},{"key":"465_CR35","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2215\/CJN.03470410","volume":"5","author":"A Gulati","year":"2010","unstructured":"Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010;5:2207\u201312.","journal-title":"Clin J Am Soc Nephrol"},{"key":"465_CR36","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(01)06573-4","volume":"358","author":"P Quartier","year":"2001","unstructured":"Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358:1511\u20133.","journal-title":"Lancet"},{"key":"465_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ndt\/gfl573","volume":"22","author":"CF Wong","year":"2007","unstructured":"Wong CF. Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence? Nephrol Dial Transplant. 2007;22:32\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"465_CR38","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834\u201340.","journal-title":"Blood"},{"key":"465_CR39","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","volume":"24","author":"MC Chaumais","year":"2009","unstructured":"Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschenes G. Fata pulmonary fibrosis after rituximab administration. Pediatr Nephrol. 2009;24:1753\u20135.","journal-title":"Pediatr Nephrol"},{"key":"465_CR40","first-page":"e243","volume":"126","author":"DS Ardelean","year":"2010","unstructured":"Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, et al. Severe ulcerative colitis after rituximab therapy. Pediatr Nephrol. 2010;126:e243\u20136.","journal-title":"Pediatr Nephrol"},{"key":"465_CR41","doi-asserted-by":"publisher","first-page":"c98","DOI":"10.1159\/000319656","volume":"117","author":"H Sugiura","year":"2011","unstructured":"Sugiura H, Takei T, Itabashi M, Tsukada M, Moriyama T, Kojima C, et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract. 2011;117:c98\u2013105.","journal-title":"Nephron Clin Pract"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-011-0465-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-011-0465-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-011-0465-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-011-0465-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T14:23:55Z","timestamp":1592576635000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-011-0465-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1007\/s10157-011-0465-6","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}